Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
3.670
-0.100 (-2.65%)
At close: Feb 27, 2026, 4:00 PM EST
3.653
-0.017 (-0.45%)
After-hours: Feb 27, 2026, 7:57 PM EST
Recursion Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 74.68 | 58.84 | 44.58 | 39.84 | 10.18 | |
| Revenue Growth (YoY) | 26.92% | 32.00% | 11.88% | 291.46% | 156.89% | |
| Cost of Revenue | 546.22 | 359.66 | 283.81 | 203.97 | 135.27 | |
| Gross Profit | -471.54 | -300.82 | -239.24 | -164.13 | -125.09 | |
| Selling, General & Admin | 176.59 | 178.18 | 110.82 | 81.6 | 57.68 | |
| Operating Expenses | 176.59 | 178.18 | 110.82 | 81.6 | 57.68 | |
| Operating Income | -648.13 | -479 | -350.06 | -245.73 | -182.78 | |
| Interest Expense | -1.81 | -1.57 | -0.1 | -0.06 | -2.95 | |
| Interest & Investment Income | 22.79 | 15.76 | 19.12 | 6.25 | 0.07 | |
| Other Non Operating Income (Expenses) | -17.74 | 0.03 | -1.09 | 0.05 | 0 | |
| EBT Excluding Unusual Items | -644.9 | -464.79 | -332.13 | -239.48 | -185.65 | |
| Other Unusual Items | - | - | - | - | -0.83 | |
| Pretax Income | -644.9 | -464.79 | -332.13 | -239.48 | -186.48 | |
| Income Tax Expense | -0.14 | -1.13 | -4.06 | - | - | |
| Net Income | -644.76 | -463.66 | -328.07 | -239.48 | -186.48 | |
| Net Income to Common | -644.76 | -463.66 | -328.07 | -239.48 | -186.48 | |
| Shares Outstanding (Basic) | 447 | 274 | 208 | 176 | 125 | |
| Shares Outstanding (Diluted) | 447 | 274 | 208 | 176 | 125 | |
| Shares Change (YoY) | 63.18% | 31.92% | 18.41% | 40.04% | 475.48% | |
| EPS (Basic) | -1.44 | -1.69 | -1.58 | -1.36 | -1.49 | |
| EPS (Diluted) | -1.44 | -1.69 | -1.58 | -1.36 | -1.49 | |
| Free Cash Flow | -378.28 | -372.87 | -299.74 | -120.58 | -198.41 | |
| Free Cash Flow Per Share | -0.84 | -1.36 | -1.44 | -0.69 | -1.58 | |
| Operating Margin | -867.87% | -814.09% | -785.33% | -616.74% | -1795.79% | |
| Profit Margin | -863.35% | -788.02% | -735.99% | -601.05% | -1832.18% | |
| Free Cash Flow Margin | -506.52% | -633.71% | -672.43% | -302.64% | -1949.42% | |
| EBITDA | -564.43 | -442.51 | -325.66 | -233.97 | -174.37 | |
| D&A For EBITDA | 83.7 | 36.49 | 24.4 | 11.76 | 8.41 | |
| EBIT | -648.13 | -479 | -350.06 | -245.73 | -182.78 | |
| Revenue as Reported | 74.68 | 58.84 | 44.58 | 39.84 | 10.18 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.